Department of Intensive Care Unit, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China.
Institute of Biomedical Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China.
Clinics (Sao Paulo). 2019;74:e509. doi: 10.6061/clinics/2019/e509. Epub 2019 Aug 12.
Acute respiratory distress syndrome (ARDS) is a life-threatening illness characterized by a complex pathophysiology, involving not only the respiratory system but also nonpulmonary distal organs. Although advances in the management of ARDS have led to a distinct improvement in ARDS-related mortality, ARDS is still a life-threatening respiratory condition with long-term consequences. A better understanding of the pathophysiology of this condition will allow us to create a personalized treatment strategy for improving clinical outcomes. In this article, we present a general overview p38 mitogen-activated protein kinase (p38MAPK) and recent advances in understanding its functions. We consider the potential of the pharmacological targeting of p38MAPK pathways to treat ARDS.
急性呼吸窘迫综合征（ARDS）是一种危及生命的疾病，其病理生理学十分复杂，不仅涉及呼吸系统，还涉及非肺部的远隔器官。尽管 ARDS 管理方面的进展显著改善了与 ARDS 相关的死亡率，但 ARDS 仍然是一种危及生命的呼吸系统疾病，会带来长期后果。更好地了解这种疾病的病理生理学将使我们能够制定个性化的治疗策略，以改善临床结局。本文概述了 p38 丝裂原活化蛋白激酶（p38MAPK）的一般情况及其功能的最新进展。我们考虑了针对 p38MAPK 途径进行药理学靶向治疗 ARDS 的潜力。
